Literature DB >> 24687455

Simvastatin treatment enhances NMDAR-mediated synaptic transmission by upregulating the surface distribution of the GluN2B subunit.

Marc-Alexander L T Parent1, David A Hottman, Shaowu Cheng, Wei Zhang, Lori L McMahon, Li-Lian Yuan, Ling Li.   

Abstract

The ramifications of statins on plasma cholesterol and coronary heart disease have been well documented. However, there is increasing evidence that inhibition of the mevalonate pathway may provide independent neuroprotective and procognitive pleiotropic effects, most likely via inhibition of isoprenoids, mainly farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). FPP and GGPP are the major donors of prenyl groups for protein prenylation. Modulation of isoprenoid availability impacts a slew of cellular processes including synaptic plasticity in the hippocampus. Our previous work has demonstrated that simvastatin (SV) administration improves hippocampus-dependent spatial memory, rescuing memory deficits in a mouse model of Alzheimer's disease. Treatment of hippocampal slices with SV enhances long-term potentiation (LTP), and this effect is dependent on the activation of Akt (protein kinase B). Further studies showed that SV-induced enhancement of hippocampal LTP is driven by depletion of FPP and inhibition of farnesylation. In the present study, we report the functional consequences of exposure to SV at cellular/synaptic and molecular levels. While application of SV has no effect on intrinsic membrane properties of CA1 pyramidal neurons, including hyperpolarization-activated cyclic-nucleotide channel-mediated sag potentials, the afterhyperpolarization (AHP), and excitability, SV application potentiates the N-methyl D-aspartate receptor (NMDAR)-mediated contribution to synaptic transmission. In mouse hippocampal slices and human neuronal cells, SV treatment increases the surface distribution of the GluN2B subunit of the NMDAR without affecting cellular cholesterol content. We conclude that SV-induced enhancement of synaptic plasticity in the hippocampus is likely mediated by augmentation of synaptic NMDAR components that are largely responsible for driving synaptic plasticity in the CA1 region.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24687455      PMCID: PMC4142643          DOI: 10.1007/s10571-014-0051-z

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  44 in total

1.  Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

Authors:  K Fassbender; M Simons; C Bergmann; M Stroick; D Lutjohann; P Keller; H Runz; S Kuhl; T Bertsch; K von Bergmann; M Hennerici; K Beyreuther; T Hartmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

2.  Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1.

Authors:  Rui M Costa; Nikolai B Federov; Jeff H Kogan; Geoffrey G Murphy; Joel Stern; Masuo Ohno; Raju Kucherlapati; Tyler Jacks; Alcino J Silva
Journal:  Nature       Date:  2002-01-16       Impact factor: 49.962

3.  Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation.

Authors:  R A Mans; L L McMahon; L Li
Journal:  Neuroscience       Date:  2011-12-13       Impact factor: 3.590

Review 4.  Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations.

Authors:  Nina E Shepardson; Ganesh M Shankar; Dennis J Selkoe
Journal:  Arch Neurol       Date:  2011-11

5.  Regulation of long-term potentiation by H-Ras through NMDA receptor phosphorylation.

Authors:  T Manabe; A Aiba; A Yamada; T Ichise; H Sakagami; H Kondo; M Katsuki
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

6.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

7.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

Authors:  B Wolozin; W Kellman; P Ruosseau; G G Celesia; G Siegel
Journal:  Arch Neurol       Date:  2000-10

8.  Estradiol-induced increase in novel object recognition requires hippocampal NR2B-containing NMDA receptors.

Authors:  Lindsey C Vedder; Caroline C Smith; Alaina E Flannigan; Lori L McMahon
Journal:  Hippocampus       Date:  2012-09-11       Impact factor: 3.899

9.  Farnesyltransferase haplodeficiency reduces neuropathology and rescues cognitive function in a mouse model of Alzheimer disease.

Authors:  Shaowu Cheng; Dongfeng Cao; David A Hottman; LiLian Yuan; Martin O Bergo; Ling Li
Journal:  J Biol Chem       Date:  2013-10-17       Impact factor: 5.157

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  9 in total

1.  Systemic or Forebrain Neuron-Specific Deficiency of Geranylgeranyltransferase-1 Impairs Synaptic Plasticity and Reduces Dendritic Spine Density.

Authors:  David Hottman; Shaowu Cheng; Andrea Gram; Kyle LeBlanc; Li-Lian Yuan; Ling Li
Journal:  Neuroscience       Date:  2018-02-02       Impact factor: 3.590

2.  Loss of TREM2 Confers Resilience to Synaptic and Cognitive Impairment in Aged Mice.

Authors:  Wenhui Qu; Ling Li
Journal:  J Neurosci       Date:  2020-11-02       Impact factor: 6.167

3.  Cholesterol intake and statin use regulate neuronal G protein-gated inwardly rectifying potassium channels.

Authors:  Anna N Bukiya; Paul S Blank; Avia Rosenhouse-Dantsker
Journal:  J Lipid Res       Date:  2018-11-12       Impact factor: 5.922

4.  Neovascularization and Synaptic Function Regulation with Memantine and Rosuvastatin in a Rat Model of Chronic Cerebral Hypoperfusion.

Authors:  Nan Zhang; Chenchen Song; Baomin Zhao; Mengya Xing; Lanlan Luo; Marc L Gordon; Yan Cheng
Journal:  J Mol Neurosci       Date:  2017-09-17       Impact factor: 3.444

5.  Simvastatin Blocks Reinstatement of Cocaine-induced Conditioned Place Preference in Male Mice with Brain Lipidome Remodeling.

Authors:  Wei Xu; Yuman He; Jiamei Zhang; Hongchun Li; Xuemei Wan; Menglu Li; Yonghai Wang; Rui Xu; Haoluo Zhang; Yanping Dai; Haxiaoyu Liu; Linhong Jiang; Ying Zhao; Xiaobo Cen
Journal:  Neurosci Bull       Date:  2021-09-07       Impact factor: 5.203

Review 6.  Regulation of Small GTPase Prenylation in the Nervous System.

Authors:  Jairus M Reddy; Namrata G R Raut; Jennifer L Seifert; DiAnna L Hynds
Journal:  Mol Neurobiol       Date:  2020-01-27       Impact factor: 5.590

7.  Simvastatin Enhances Activity and Trafficking of α7 Nicotinic Acetylcholine Receptor in Hippocampal Neurons Through PKC and CaMKII Signaling Pathways.

Authors:  Tingting Chen; Ya Wang; Tingting Zhang; Baofeng Zhang; Lei Chen; Liandong Zhao; Ling Chen
Journal:  Front Pharmacol       Date:  2018-04-12       Impact factor: 5.810

8.  Neuronal Protein Farnesylation Regulates Hippocampal Synaptic Plasticity and Cognitive Function.

Authors:  Wenhui Qu; Kiall F Suazo; Wenfeng Liu; Shaowu Cheng; Angela Jeong; David Hottman; Li-Lian Yuan; Mark D Distefano; Ling Li
Journal:  Mol Neurobiol       Date:  2020-10-24       Impact factor: 5.590

9.  A Differential Effect of Lovastatin versus Simvastatin in Neurodevelopmental Disorders.

Authors:  Melania Muscas; Sang S Seo; Susana R Louros; Emily K Osterweil
Journal:  eNeuro       Date:  2020-08-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.